India-based CDMO OneSource Specialty Pharma has entered a strategic manufacturing partnership with German biosimilar developer Formycon AG. Under the agreement, OneSource will provide integrated Drug Substance (DS) and Drug Product (DP) manufacturing services from its biologics facility in Bangalore to support Formycon's global biosimilar programs.
BANGALORE, INDIA — OneSource Specialty Pharma Limited has officially finalized a strategic manufacturing partnership for biosimilars with German therapeutic developer Formycon AG. The supply-chain agreement marks a significant expansion of high-end biopharmaceutical production capabilities within the South Asian region.
Under the operational terms of the agreement finalized on July 14, 2026, OneSource will act as a core contract development and manufacturing organization (CDMO) partner for the Munich-based biomanufacturer. The commercial workflow will deliver end-to-end integrated Drug Substance (DS) and Drug Product (DP) solutions out of OneSource's state-of-the-art biologics hub located in Bangalore, India. The specialized alliance targets the high-volume fulfillment of advanced biological therapies across strictly regulated Western and emerging international medicine markets.
Technical Scope of the Bangalore Biologics Allocation
The manufacturing alliance addresses the structural demand for scalable, high-fidelity biological drug manufacturing. Corporate statements submitted to the National Stock Exchange of India (NSE) indicate that OneSource will utilize its newly expanded mammalian and microbial expression lines to manufacture Formycon’s complex therapeutic molecules. The integration combines bulk active ingredient fermentation—classified as Drug Substance—with sterile automated vial filling, finishing, and analytical testing protocols—referred to as Drug Product execution.
By operating both production phases under a singular infrastructure canopy in Bangalore, the partnership minimizes international cold-chain shipping logistics, reduces cross-border transfer risks, and optimizes baseline yield metrics. The production schedules are aligned with global regulatory baselines, including Current Good Manufacturing Practice (cGMP) standards validated by the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA).
Commercial Alignment and Pipeline Support
The strategic collaboration directly reinforces Formycon’s long-term commercial trajectory, structured under its global "FYB4Growth" corporate strategy. Formycon maintains an active late-stage pipeline of follow-on biological products, including biosimilar candidates targeting heavy-volume indications in ophthalmology, immunology, and oncology. This includes specialized treatments like FYB203 (aflibercept) slated for broader availability, alongside automated scale-up phases for oncology therapeutics like FYB206 (pembrolizumab).
For OneSource Specialty Pharma, which transitioned to the public domain under listed ticker markers BSE: 544292, the contract serves as an important validation of its dedicated multi-modality CDMO business model. The Bangalore site features high-capacity automated flexible assembly lines capable of handling multiple complex dosage presentations, including prefilled syringes, dial-and-push variable pen injectors, and lyophilized sterile liquid vials. The multi-year contract expands OneSource’s existing biologics order funnel, adding predictable, recurring service revenue to its core legacy portfolio of soft gelatin capsules and sterile injectables.
Official Sources Section
The corporate frameworks, operational sites, and manufacturing parameters detailed in this report are based directly on joint regulatory press releases issued by Formycon AG and official corporate disclosures submitted by OneSource Specialty Pharma Limited to the National Stock Exchange of India (NSE) and BSE Limited listing desks.
Quote Section
Commenting on the strategic supply-chain integration, Dr. Stefan Glombitza, Chief Executive Officer of Formycon AG, stated:
“Reliable, scalable and cost-efficient manufacturing is a cornerstone of our FYB4Growth strategy. By adding OneSource to our network of strategic manufacturing partners, we are further strengthening our supply capabilities with a partner that meets our unwavering commitment to high standards of quality, operational excellence and cost-efficiency.”
Neeraj Sharma, Managing Director and CEO of OneSource Specialty Pharma, added:
“This partnership brings together Formycon's development expertise and OneSource's end-to-end biologics manufacturing expertise to support Formycon's biosimilar programs for global markets.”
Why It Matters
For global patients and national healthcare systems, the integration of advanced European development with efficient Indian manufacturing helps speed up the availability of affordable, life-saving biological treatments, directly lowering medical costs for severe chronic illnesses. For biotech investors, the multi-year deal provides OneSource with reliable revenue visibility while allowing Formycon to scale up production without building expensive new factories. Additionally, the deal strengthens Bangalore's reputation as a key global hub for high-tech biomanufacturing and sterile drug-device assembly.
Key Facts at a Glance
Strategic Partnership: Signed a definitive international manufacturing agreement for advanced biosimilars.
Operational Center: Manufacturing will be managed entirely at OneSource’s specialized biologics plant in Bangalore, India.
Integrated Production: Covers both large-scale cell line fermentation (Drug Substance) and sterile automated filling (Drug Product).
Corporate Alignment: Supports Formycon's global "FYB4Growth" expansion strategy for regulated Western markets.
Technological Capacity: Deploys advanced flexible cleanrooms capable of handling prefilled syringes and sterile liquid vials.
FAQ Section
What is the core focus of the partnership between OneSource and Formycon?
The strategic partnership centers on contract manufacturing, where OneSource will supply integrated Drug Substance and Drug Product services to support Formycon's expanding portfolio of biosimilars.
Where will the actual production of these biological therapies take place?
All manufacturing, testing, and automated filling operations will be handled at OneSource Specialty Pharma’s advanced biologics facility located in Bangalore, India.
How do biosimilars differ from standard generic chemical medications?
Unlike traditional small-molecule chemical generics, biosimilars are large, highly complex molecules grown in living cells using advanced biotechnology, requiring strict manufacturing quality controls to match the reference biological drug.
Source: National Stock Exchange of India (NSE); BSE Limited; Formycon AG Investor Relations Bureau; OneSource Specialty Pharma Limited Corporate Disclosures.
